Hikma Pharmaceuticals PLC (LON:HIK) Receives GBX 2,068.75 Consensus Price Target from Brokerages

Hikma Pharmaceuticals PLC (LON:HIK) has been given an average rating of “Moderate Buy” by the six analysts that are covering the company, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is GBX 2,068.75 ($25.75).

HIK has been the topic of several recent research reports. Berenberg Bank increased their price objective on Hikma Pharmaceuticals from GBX 1,960 ($24.40) to GBX 2,000 ($24.90) and gave the stock a “hold” rating in a research report on Monday, February 26th. Barclays restated an “equal weight” rating and issued a GBX 2,000 ($24.90) price target on shares of Hikma Pharmaceuticals in a research report on Monday, April 8th.

Hikma Pharmaceuticals Stock Up 0.6 %

HIK stock opened at GBX 1,799 ($22.40) on Wednesday. The company has a debt-to-equity ratio of 53.92, a current ratio of 1.57 and a quick ratio of 1.27. The stock has a market capitalization of £3.99 billion, a price-to-earnings ratio of 2,685.07, a PEG ratio of 2.38 and a beta of 0.45. The business’s fifty day moving average price is GBX 1,900.77 and its two-hundred day moving average price is GBX 1,877.24. Hikma Pharmaceuticals has a fifty-two week low of GBX 1,711 ($21.30) and a fifty-two week high of GBX 2,222 ($27.66).

Hikma Pharmaceuticals Increases Dividend

The business also recently declared a dividend, which will be paid on Friday, May 3rd. Investors of record on Thursday, March 21st will be given a $0.47 dividend. The ex-dividend date is Thursday, March 21st. This represents a dividend yield of 1.86%. This is a boost from Hikma Pharmaceuticals’s previous dividend of $0.25. Hikma Pharmaceuticals’s dividend payout ratio (DPR) is presently 8,507.46%.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.